CA3024783A1 - Therapeutic uses of l-4-chlorokynurenine - Google Patents
Therapeutic uses of l-4-chlorokynurenine Download PDFInfo
- Publication number
- CA3024783A1 CA3024783A1 CA3024783A CA3024783A CA3024783A1 CA 3024783 A1 CA3024783 A1 CA 3024783A1 CA 3024783 A CA3024783 A CA 3024783A CA 3024783 A CA3024783 A CA 3024783A CA 3024783 A1 CA3024783 A1 CA 3024783A1
- Authority
- CA
- Canada
- Prior art keywords
- chlorokynurenine
- depression
- dose
- treatment
- tinnitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562179924P | 2015-05-22 | 2015-05-22 | |
| US62/179,924 | 2015-05-22 | ||
| PCT/US2016/033733 WO2016191351A1 (en) | 2015-05-22 | 2016-05-23 | Therapeutic uses of l-4-chlorokynurenine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3024783A1 true CA3024783A1 (en) | 2016-12-01 |
Family
ID=57393671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3024783A Pending CA3024783A1 (en) | 2015-05-22 | 2016-05-23 | Therapeutic uses of l-4-chlorokynurenine |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20180140568A1 (enExample) |
| EP (2) | EP3297619B1 (enExample) |
| JP (3) | JP2018521007A (enExample) |
| KR (2) | KR20240068766A (enExample) |
| CN (1) | CN107949379A (enExample) |
| AU (3) | AU2016268153B2 (enExample) |
| BR (1) | BR112017024908A2 (enExample) |
| CA (1) | CA3024783A1 (enExample) |
| DK (1) | DK3297619T3 (enExample) |
| EA (1) | EA201792571A1 (enExample) |
| ES (1) | ES2925274T3 (enExample) |
| IL (3) | IL296380A (enExample) |
| MX (1) | MX395492B (enExample) |
| PL (1) | PL3297619T3 (enExample) |
| PT (1) | PT3297619T (enExample) |
| SG (1) | SG10202007661XA (enExample) |
| SI (1) | SI3297619T1 (enExample) |
| WO (1) | WO2016191351A1 (enExample) |
| ZA (1) | ZA201707874B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102257284B1 (ko) | 2013-01-22 | 2021-05-28 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP2022526427A (ja) * | 2019-04-09 | 2022-05-24 | ヴィスタゲン セラピューティクス、インコーポレイテッド | 神経障害の治療への反応に関連する遺伝的変異体 |
| US20230181541A1 (en) * | 2020-06-24 | 2023-06-15 | Biohaven Therapeutics Ltd. | Compositions and methods for treating obsessive-compulsive disorder |
| WO2022221423A1 (en) * | 2021-04-13 | 2022-10-20 | Vistagen Therapeutics, Inc. | Treatment of autoimmune anti-nmda-receptor encephalitis |
| CN115677519A (zh) * | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用 |
| WO2024011105A1 (en) * | 2022-07-05 | 2024-01-11 | Mahana Therapeutics, Inc. | Methods and systems for treating tinnitus using digital therapeutics |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484814A (en) | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| WO1999045906A1 (en) * | 1998-03-09 | 1999-09-16 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| AU2002229056A1 (en) * | 2000-12-07 | 2002-06-18 | Neuromolecular Inc. | Methods for treating neuropsychiatric disorders with NMDA receptor antagonists |
| US20060063802A1 (en) * | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| AU2007235876A1 (en) * | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| AU2008323877A1 (en) * | 2007-11-06 | 2009-05-14 | Emory University | Methods of identifying safe NMDA receptor antagonists |
| TW201026667A (en) * | 2008-09-30 | 2010-07-16 | Merz Pharma Gmbh & Co Kgaa | Glycine b antagonists |
| CN104902883A (zh) * | 2012-08-23 | 2015-09-09 | 斯图亚特·L·韦格 | 抗焦虑组合物、制剂及使用方法 |
| KR102257284B1 (ko) * | 2013-01-22 | 2021-05-28 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| CA2941559A1 (en) | 2013-03-14 | 2014-09-25 | Vistagen Therapeutics, Inc. | Methods for the synthesis of chiral kynurenine compounds |
| EP2970080A4 (en) | 2013-03-14 | 2017-01-18 | Vistagen Therapeutics, Inc. | Synthesis of chiral kynurenine compounds and intermediates |
| BR112016025910A8 (pt) * | 2014-05-06 | 2021-07-13 | Univ Northwestern | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos |
-
2016
- 2016-05-23 CA CA3024783A patent/CA3024783A1/en active Pending
- 2016-05-23 DK DK16800590.8T patent/DK3297619T3/da active
- 2016-05-23 BR BR112017024908A patent/BR112017024908A2/pt not_active Application Discontinuation
- 2016-05-23 EP EP16800590.8A patent/EP3297619B1/en active Active
- 2016-05-23 WO PCT/US2016/033733 patent/WO2016191351A1/en not_active Ceased
- 2016-05-23 EA EA201792571A patent/EA201792571A1/ru unknown
- 2016-05-23 SI SI201631606T patent/SI3297619T1/sl unknown
- 2016-05-23 ES ES16800590T patent/ES2925274T3/es active Active
- 2016-05-23 AU AU2016268153A patent/AU2016268153B2/en active Active
- 2016-05-23 PL PL16800590.8T patent/PL3297619T3/pl unknown
- 2016-05-23 EP EP22183035.9A patent/EP4108239A1/en not_active Withdrawn
- 2016-05-23 SG SG10202007661XA patent/SG10202007661XA/en unknown
- 2016-05-23 IL IL296380A patent/IL296380A/en unknown
- 2016-05-23 CN CN201680042400.6A patent/CN107949379A/zh active Pending
- 2016-05-23 PT PT168005908T patent/PT3297619T/pt unknown
- 2016-05-23 MX MX2017014456A patent/MX395492B/es unknown
- 2016-05-23 US US15/576,319 patent/US20180140568A1/en not_active Abandoned
- 2016-05-23 JP JP2017560663A patent/JP2018521007A/ja active Pending
- 2016-05-23 KR KR1020247014693A patent/KR20240068766A/ko not_active Ceased
- 2016-05-23 KR KR1020177036471A patent/KR20180015158A/ko not_active Ceased
-
2017
- 2017-11-20 IL IL255770A patent/IL255770B/en unknown
- 2017-11-20 ZA ZA2017/07874A patent/ZA201707874B/en unknown
-
2019
- 2019-05-06 US US16/403,974 patent/US20190321317A1/en not_active Abandoned
-
2021
- 2021-07-29 AU AU2021209279A patent/AU2021209279B2/en active Active
- 2021-08-25 IL IL285882A patent/IL285882A/en unknown
-
2022
- 2022-01-17 JP JP2022004811A patent/JP2022064908A/ja active Pending
- 2022-09-30 US US17/958,169 patent/US20240122887A1/en not_active Abandoned
-
2023
- 2023-12-13 AU AU2023282234A patent/AU2023282234A1/en not_active Abandoned
-
2024
- 2024-01-04 JP JP2024000227A patent/JP2024050575A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021209279B2 (en) | Therapeutic uses of L-4-chlorokynurenine | |
| Detke et al. | Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial | |
| Winblad et al. | Therapeutic use of nicergoline | |
| Post et al. | Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response | |
| JP2019023195A (ja) | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 | |
| JP2008509147A (ja) | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 | |
| WO2020068913A1 (en) | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | |
| HK1257800B (en) | Therapeutic uses of l-4-chlorokynurenine | |
| US20130261165A1 (en) | Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death | |
| HK40022228B (en) | Dosage forms and therapeutic uses l-4- chlorokynurenine | |
| HK40022228A (en) | Dosage forms and therapeutic uses l-4- chlorokynurenine | |
| NZ710121B2 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |
|
| EEER | Examination request |
Effective date: 20210521 |